jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

Cash from an ex-U.S. licensing deal with Santen, plus years of grants from CIRM, position jCyte to bring its genetic blindness stem cell therapy into pivotal studies.

Santen Pharmaceutical Co. Ltd. (Tokyo:4536) will receive exclusive rights to jCell in regions that include Europe and Asia. The human allogeneic retinal progenitor cell therapy is in the crossover portion of a Phase IIb study to treat retinitis pigmentosa...